Mayo Clinic is ramping up activity in the remote patient monitoring arena. Its latest move is a collaboration with biomedical technology company NXgenPort, which will focus on an implantable catheter that can remotely monitor cancer patients for complications as they undergo treatment.
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
By Natalie Missakian
AI-driven health intelligence company Sema4 announced Wednesday morning that it is merging with a “blank check” company and going public in a deal that values the Stamford-based startup at $2 billion.
The rapidly growing company, which also has a lab in Branford, said its merger with CM Life Sciences is expected to close during the second quarter of this year, pending approval from CM shareholders.
The combined company will be listed on the Nasdaq under a to-be-announced name and ticker symbol, Sema4 said.
CM Life Sciences is a special purpose acquisition company, or SPAC, led by health care investment firm Casdin Capital and hedge fund Corvex Management, both of which are based in New York.